26 Jul 2019 07:00
RNS
Horizon Discovery Group plc
Block Listing Six Monthly Return and Block Listing Application
26 July 2019: Horizon Discovery Group plc (LSE: HZD) ("Horizon") provides the following update in accordance with Schedule Six of the AIM Rules for Companies regarding its existing block listing arrangements:
Name of applicant: | Horizon Discovery Group plc | |
Name of scheme(s): | a) Horizon Discovery Limited Enterprise Management Incentive Share Option Scheme b) Horizon Discovery Group plc Long Term Incentive Plan c) Horizon Discovery 2014 Sharesave Scheme d) Horizon Discovery Group plc US Employee Stock Purchase Plan | |
Period of return (from / to): | From: 26 January 2019 | To: 25 July 2019 |
Number of securities admitted and date of admission | Total of 3,000,000 ordinary shares of 1p each, admission date 26 July 2017, split: a) 1,398,000 b) 1,392,000 c) 110,000 d) 100,000 Further 500,000 ordinary shares of 1p each, admission date 27 July 2018, split: a) 0 b) 150,000 c) 150,000 d) 200,000
| |
Balance of unallotted securities under schemes from previous return: | Total of 1,756,424 ordinary shares of 1p each, split a) 616,750 b) 926,020 c) 98,065 d) 115,589
| |
Plus: The amount by which the block scheme(s) has been increased or application has been made to increase since the date of the last return (if any increase has been applied for): | 0
| |
Less: Number of securities issued/allotted under scheme(s) during period: | Total of 32,432 ordinary shares of 1p each, split a) 7,000 b) 13,127 c) 12,305 d) 0 | |
Equals: Balance under scheme(s) not yet issued/allotted at end of period: | Total of 1,723,992 ordinary shares of 1p each, split a) 609,750 b) 912,893 c) 85,760 d) 115,589 | |
ENDS
For further information from Horizon Discovery Group plc, please contact:
Horizon Discovery Group plc
Terry Pizzie, Chief Executive Officer
Jayesh Pankhania, Chief Financial Officer
Jon Davies, Head of Investor Relations
Tel: +44 (0) 1223 655 580
Numis Securities Limited (Broker and NOMAD)
Freddie Barnfield / Tom Ballard / Duncan Monteith
Tel: +44 (0) 207 260 1000
Consilium Strategic Communications (Financial Media and Investor Relations)
Mary-Jane Elliott / Matthew Neal / Melissa Gardiner
Tel: +44 (0) 20 3709 5700
Email: horizon@consilium-comms.com
About Horizon Discovery Group plc www.horizondiscovery.com
Horizon Discovery Group plc (LSE: HZD) ("Horizon") drives the application of gene editing and gene modulation within the global life science market - supporting scientists on the path from research to therapy.
Built upon more than a decade of experience in the engineering of cell lines, Horizon offers an unmatched portfolio of tools and services to help scientists gain a greater understanding of gene function, identify genetic drivers behind human disease, deliver biotherapeutics, cellular and gene therapies for precision medicine as well as develop and validate diagnostic workflows.
Horizon's solutions enable almost any gene to be altered, or its function modulated, in human and other mammalian cell lines.
The Company's customers include many of the world's foremost academic institutes, global pharmaceutical and biotechnology companies as well as clinical diagnostic laboratories. Insight into the challenges faced by these organizations enables Horizon to focus efforts on development of innovative solutions that not only differentiate the Company's offering, but also fuel development of the next wave of precision medicines.
Horizon is headquartered in Cambridge, UK with offices in USA and Japan. The Group is listed on the London Stock Exchange's AIM market under the ticker HZD.